Moderna and Generation Bio plan to develop non-viral genetic medicines for immune system and liver disorders under an up-to-$1.9 billion collaboration.
Nabla Bio, a Boston, Massachusetts based startup, announced a $11 million seed round on Monday. The company, founded in May 2020, is looking to enter the increasingly competitive space of antibody design, and manufacturing. Nabla Bio, in essence, is an antibody design platform. The company is working with technology refined by Nabla Bio co-founder Surge […]